FAS has sent the government proposals to support the production of cheap drugs

The Federal Antimonopoly service (FAS) has prepared and submitted to the government of the Russian Federation proposals on the support of the Russian manufacturers of medicines costing less than 100 rubles, said Deputy head of FAS Andrey tsarikovskiy.

“We represent some problem of the Russian manufacturers of cheap drugs, below $ 100. There are many problems, because sometimes it is simply not profitable to produce and trade in such drugs. We have sent the government a number of measures proposed for the conservation of just producers of cheap drugs”, – quotes RIA Novosti words Tsarikovsky.

Previously, the Agency stated that the proposed FAS approach will reduce the risk of care essential medicines of the lower price segment of the market that will ensure their availability for the population. In the FAS noted that this issue was long overdue and is systemic.

Leave a Reply

Your email address will not be published. Required fields are marked *

Releated

“Nanolek” released the first batch of hydroxychloroquine

The company “Nanolek” factory in the Kirov region has established the production of one of the drugs for the treatment of coronavirus infection of hydroxychloroquine. Currently, hydroxychloroquine is included in the treatment protocols in the interim Ministry of health recommendations for the prevention, diagnosis and treatment of new coronavirus infection. The first batch of this […]

Igor Ghahramanyan was returned to the Ministry of health

Senator Igor Ghahramanyan was appointed first Deputy Minister of health of the Russian Federation. In the Federation Council Ghahramanyan presented the Executive authority of the Yaroslavl region and held the position of first Deputy Chairman of Committee on social policy, writes “Kommersant”. From 2012 to 2017 Igor Ghahramanyan was already a Deputy and first Deputy […]

AstraZeneca localized in Russia production of ticagrelor

Company AstraZeneca localized at its own plant in Kaluga region manufacture of the finished dosage form of ticagrelor 90 mg for the treatment of patients with acute coronary syndrome (ACS). Ticagrelor (trade name of Brilinta) is included in the list of essential drugs and included in the standards of specialized medical care for patients with […]